And the FDAs reasoning? The outside chance it may have carcinogens?
This decision is the last step in an ongoing FDA investigation into a probable carcinogenic contaminant, N-nitrosodimethylamine (NDMA), found in some ranitidine products. NDMA is an impurity that increases in amount over time and when the product is stored at or exposed to greater than room temperatures.
The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S.
And a White Paper from the National Library of Medicine:
With the world threatened by a second surge in the number of Coronavirus cases, there is an urgent need for the development of effective treatment for the novel coronavirus (COVID-19). Recently, global attention has turned to preliminary reports on the promising anti-COVID-19 effect of histamine H2-receptor antagonists (H2RAs), most especially Famotidine. Therefore, this study was designed to exploit a possible molecular basis for the efficacy of H2RAs against coronavirus. Molecular docking was performed between four H2RAs, Cimetidine, Famotidine, Nizatidine, Ranitidine, and three non-structural proteins viz. NSP3, NSP7/8 complex, and NSP9. Thereafter, a 100 ns molecular dynamics simulation was carried out with the most outstanding ligands to determine the stability. Thereafter, Famotidine and Cimetidine were subjected to gene target prediction analysis using HitPickV2 and eXpression2Kinases server to determine the possible network of genes associated with their anti-COVID activities. Results obtained from molecular docking showed the superiority of Famotidine and Cimetidine compared to other H2RAs with a higher binding affinity to all selected targets. Molecular dynamic simulation and MMPBSA results revealed that Famotidine as well as Cimetidine bind to non-structural proteins more efficiently with high stability over 100 ns. Results obtained suggest that Famotidine and Cimetidine could be a viable option to treat COVID-19 with a mechanism of action that involves the inhibition of viral replication through the inhibition of non-structural proteins. Therefore, Famotidineand Cimetidine qualify for further study as a potential treatment for COVID-19.
Notice that Ranitidine, the active ingredient in Zantac, is included in the above paragraph.
Wrong. You would believe the FDA? WTF have we learned nothing? The FDA was eyeballs deep in this bioweapon op from day 1. SMDH
From that bastion of conservative thought "Nature" magazine:
https://www.nature.com/articles/s41564-020-00802-x
And the FDAs reasoning? The outside chance it may have carcinogens?
https://www.the-rheumatologist.org/article/baricitinib-studied-as-possible-covid-19-treatment-plus-ranitidine-removed-from-u-s-market/
Also:
https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market
And a White Paper from the National Library of Medicine:
Notice that Ranitidine, the active ingredient in Zantac, is included in the above paragraph.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852284/
Not hard to find this stuff. Maybe you should check your six before you come at people with such certainty. We deal in facts here not emotion.